Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation

Lumateperone is indicated for the treatment of schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate (Calabrese et al., 2021). It is currently under evaluation fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutheil, Sophie, Watson, Luke S., Davis, Robert E., Snyder, Gretchen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Neuroscience 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899083/
https://www.ncbi.nlm.nih.gov/pubmed/36549907
http://dx.doi.org/10.1523/JNEUROSCI.0984-22.2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899083/
https://www.ncbi.nlm.nih.gov/pubmed/36549907
http://dx.doi.org/10.1523/JNEUROSCI.0984-22.2022

Ejemplares similares